Pharming Group (Pharming Group) YoY EBITDA Growth : 156.52% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Pharming Group YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Pharming Group's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 156.52%.

Pharming Group's EBITDA per Share for the three months ended in Dec. 2023 was $0.08.

Pharming Group YoY EBITDA Growth Historical Data

The historical data trend for Pharming Group's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group YoY EBITDA Growth Chart

Pharming Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

179.21

-19.42

-18.60

-31.90

-71.31

Pharming Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															-157.26	-259.29	-67.64	-39.01	156.52

Pharming Group YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Pharming Group's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(0.136	-	0.474)	/	\| 0.474 \|
=	-71.31 %

Pharming Group's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(0.078	-	-0.138)	/	\| -0.138 \|
=	156.52 %

Pharming Group YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Pharming Group's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group (Pharming Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

PHGUF:USA PHARM:Netherlands PHARMa:UK 0QCO:UK PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on developing and producing human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. The revenue is generated from the United States.